The most common adverse effects found in the clinical trials were nausea, headache, diarrhea, vomiting, and dizziness.<ref name="Prescribing Info"/> Tedizolid has also been found to have hematologic (blood) effects, as shown in [[phase I clinical trial|Phase-I]] studies in which subjects exposed to doses longer than 6 days showed a possible dose and duration effect on hematologic parameters.<ref name="Prescribing Info"/>  Its safety in patients with decreased levels of white blood cells has not been established.<ref name="FDA Approval"/>  Patients on tedizolid are also at low risk of peripheral and [[optic neuropathy]], similar to other members of the oxazolidinone class.<ref name="Prescribing Info"/>

 

